Skip to content

Arcutis Biotherapeutics

US · ARQT #2465 by market cap Listed 2020
24.17 +0.25 +1.05%
Live - 5344 symbols - heartbeat 297s ago · 2026-10-07 20:02
After-hours 24.17 0.00%
Market cap
3.04B
P/B
13.77
EPS
-0.13
Reader sentiment Are you bullish or bearish on ARQT?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/7/1
  • Rating change
    A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37
    Market Newswire · 2026/2/27
  • Rating change
    Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Cuts Target Price to $35
    Market Newswire · 2026/2/28
  • Rating change
    Goldman Sachs Maintains Arcutis Biotherapeutics(ARQT.US) With Hold Rating, Raises Target Price to $33
    Market Newswire · 2026/2/27
  • Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/7/15
  • Rating change
    TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/1/29
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)
    TipRanks · 2026/5/26
  • Rating change
    A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36
    Market Newswire · 2026/5/8
  • H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34
    Market Newswire · 2026/8/11
  • Rating change
    Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/5/26
  • A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $40
    Market Newswire · 2026/8/7
  • Rating change
    Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $37
    Market Newswire · 2026/1/27
  • Rating change
    Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/4/22
  • Rating change
    Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $35
    Market Newswire · 2026/2/27
  • Form 144 | Arcutis Biotherapeutics(ARQT.US) Insider Proposes to Sell 8.55 Million in Common Stocks
    Market Newswire · 2026/9/17
  • Rating change
    H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/2/3
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)
    TipRanks · 2026/8/11
  • Rating change
    Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $31
    Market Newswire · 2026/1/27
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN)
    TipRanks · 2026/4/22
  • Rating change
    TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/4/23

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-07 20:02:23 · For reference only, not investment advice and not tailored to your situation.